Department of Health and Human Services, through National Institutes of Health, awarded Vivid Bioinnovations, Pbc of San Francisco, CA $1,319,519 under the SBIR program, with work starting 2025-09-12 and running to 2028-08-31. It is one of 3 SBIR and STTR awards Vivid Bioinnovations, Pbc received in the last two years, $2,133,088 in all. Each figure links to the federal record.
The award
| Recipient | Vivid Bioinnovations, Pbc (San Francisco, CA) |
|---|---|
| Awarding agency | Department of Health and Human Services |
| Awarding office | National Institutes of Health |
| Amount obligated | $1,319,519 |
| Period of performance starts | 2025-09-12 |
| Period of performance ends | 2028-08-31 |
| Award number | R44AG091101 (grant, CFDA 93.866) |
| Assistance listing | 93.866, Aging Research |
| Place of performance | San Francisco, San Francisco County, CA |
| Recipient registry id (UEI) | Q1NZN4P95F83 |
Want the whole picture on Vivid Bioinnovations, Pbc?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Vivid Bioinnovations, Pbc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Vivid Bioinnovations, Pbc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
What it is for
A novel cell sorting technology to enable investigation of rare cells in primary human tissues - abstract rare cells, such as pathogenic astrocytes, play an important role in tissue physiology and pathology, including ne
Funding actions on this award
| Date | Action | Modification | Amount |
|---|---|---|---|
| 2026-08-27 | Continuation | 002 | $1,012,648 |
| 2026-08-26 | Revision | 001 | $0 |
| 2026-02-16 | Revision | 000 | $0 |
| 2025-09-12 | New | 000 | $306,871 |
Find-seq: A novel cell sorting technology to enable investigation of rare cells in primary human tissues - abstract rare cells, such as pathogenic astrocytes, play an important role in tissue physiology and pathology, including neurodegenerative and cns disorders. However, the investigation of these cells is often hindered by the lack of known surface markers to isolate them, which is necessary for in-depth profiling. Find-seq, a novel cell sorting technology developed by dr. Adam abate, a founder of fluid discovery, which enables rare cells or nuclei to be isolated based on DNA or RNA markers with single molecule sensitivity, even in cases where no known surface markers are available. Fluid discovery, is focused on commercializing find-seq for neurodegenerative disease research and broader single-cell genomics markets. This fast-track SBIR will support the translation of the technology from the lab to the company, its development into a first-generation commercial product, and its validation on an important neurodegenerative disease use-case. The successful completion of these aims is crucial for the commercialization of find-seq and for fluid discovery's ability to meet the growing demand for more effective and efficient rare cell sorting and sequencing technologies.
From the federal award record.
Other SBIR and STTR awards to Vivid Bioinnovations, Pbc
| Starts | Agency | Program | Amount | Project |
|---|---|---|---|---|
| 2026-09-08 | Department of Health and Human Services | SBIR Phase I | $506,495 | Astrotarget™ astro-enrichment kit: A microfluidic-free platform for high-throughput rare-a (record) |
| 2026-08-19 | Department of Health and Human Services | SBIR Phase I | $307,074 | A novel omics technology to profile thousands of single hiv-positive cells - abstract iden (record) |
Every other federal award to Vivid Bioinnovations, Pbc on record
The federal register lists 10 other awards to the same registry id (UEI Q1NZN4P95F83), $5,581,452 in all, from 1 agency.
| Starts | Agency | Amount | Award |
|---|---|---|---|
| 2026-09-01 | National Institutes of Health | $299,991 | Spatially resolved single-cell DNA sequencing: A general spatial genomics platform with application to HIV res (R44AI197850) |
| 2026-08-07 | National Institutes of Health | $306,872 | Ultrahigh-throughput cell interaction screening to advance car-t therapeutic development - abstract chimeric a (R44CA310740) |
| 2026-08-04 | National Institutes of Health | $300,001 | Integrated high-throughput microfluidic-mass spectrometry for enhanced biomedical data generation and AI model (R44GM163514) |
| 2025-09-01 | National Institutes of Health | $595,337 | Multiplexed nucleic acid self-test for reproducible and sensitive HIV detection (75N93025C00029) |
| 2025-08-01 | National Institutes of Health | $1,334,377 | A universal platform for ultrahigh-throughput biocatalyst evolution with micro-mass spectrometry - abstract th (R44GM161309) |
| 2024-04-01 | National Institutes of Health | $268,142 | Point-of-care viral load monitoring to support large-scale clinical testing of new HIV cure strategies - abstr (R43AI181436) |
| 2024-02-01 | National Institutes of Health | $268,142 | Single cell tri-omics: High coverage simultaneous profiling of DNA, RNA, and proteins in single cells - abstra (R43NS135703) |
| 2023-08-01 | National Institutes of Health | $299,903 | "multiplexed droplet digital nucleic acid amplification technologies for HIV diagnosis" (75N93023C00008) |
| 2021-09-25 | National Institutes of Health | $1,654,892 | A universal droplet microfluidic platform for ultrahigh-throughput biocatalyst evolution - abstract the advanc (R42GM143989) |
| 2021-09-25 | National Institutes of Health | $253,795 | Ultrahigh throughput microscale mass spectrometry for pharmaceutical prenylation enzyme engineering - project (R41GM143989) |
Who runs it, who owns it, where the money comes from and what to watch for, every claim linked to its source.
Order Full Report on Vivid Bioinnovations, PbcLook up Vivid Bioinnovations, Pbc first. Finding the company and seeing how much is on record uses no credits.
Look up Vivid Bioinnovations, PbcWhere this comes from
The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs set aside part of federal research budgets for small companies. Agencies award them in phases: Phase I tests whether an idea is feasible, Phase II funds development, and Phase III is follow-on work paid for outside the set-aside. STTR awards also require a research institution as a partner.
Every figure on this page is taken from the award's own federal record, linked beside it, as it stood when the page was built: the recipient, its address, the awarding agency and office, the amount obligated so far, the dates and the description. Phase and program are shown as the award's own description states them. The amount can grow later if the agency adds funding to the same award.